(2S)-6-azaniumyl-2-[[(2S)-2-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]hexanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-6-azaniumyl-2-[[(2S)-2-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]hexanoate
• 化学式: C16H23N3O5
• 分子量: 337.37
• InChiKey: BZUABSYGNBFITP-DDOQPMFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S)-6-azaniumyl-2-[[(2S)-2-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]propanoyl]amino]hexanoate 生成 (2S)-2-{[(E)-3-(2-furyl)-2-propenoyl]amino}propanoic acid
  参考文献：
  名称：

  GRIMWOOD, BRIAN G.;TARENTINO, ANTHONY L.;PLUMMER, THOMAS H. , JR., ANAL. BIOCHEM., 170,(1988) N 1, 264-268

  摘要：

  DOI：

文献信息

• Pharmaceuticals
  申请人：——

  公开号：US20020147229A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I) 1 as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIla inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

  本发明提供了式(I)1的化合物，以及这些化合物在制药组合物和治疗方法中的应用。本文描述的化合物代表了一类适用于治疗血栓形成、动脉粥样硬化、粘连、皮肤瘢痕、癌症、纤维化疾病、炎症性疾病以及那些受益于维持或增强体内激肽酶激活因子Ⅰ（TAFIla）抑制剂的疾病的化合物。
• CYCLOPROPANECARBOXYLIC ACID DERIVATIVE
  申请人：Nagata Tsutomu

  公开号：US20130012532A1

  公开（公告）日：2013-01-10

  A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R 1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R 2 , R 3 , and R 8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R 4 , R 5 , R 6 , R 7 , R 9 , and R 10 each independently represent a hydrogen atom or the like; and R 11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.

  以下是由下列通式（I）表示的化合物或其药学上可接受的盐，其中R1代表C1至C6烷基，该烷基可以被选自取代基A的一个至三个基团取代（取代基A：羟基、卤素基、氰基、硝基、氨基、羧基、C1至C3烷基等）；R2、R3和R8各自独立地代表氢原子或C1至C3烷基；R4、R5、R6、R7、R9和R10各自独立地代表氢原子或类似物；而R11代表氢原子或类似物。该化合物具有TAFIa酶抑制活性，可用作治疗心肌梗塞、心绞痛、急性冠状动脉综合征、脑梗死、深静脉血栓、肺栓塞等疾病的治疗药物。
• 3-(Imidazolyl)-2-aminopropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030191107A1

  公开（公告）日：2003-10-09

  Compounds according to formula (I) wherein n is 1-4, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式(I)，其中n为1-4，R1是可选取代的C1-6烷基、C2-6烯基或C2-6炔基、杂环、芳香杂环、芳基或氢，而R2、R3、R4、R5、R6、R7和R8各自独立选择自氢和可选取代的C1-6烷基的化合物是新颖的。它们在治疗血栓症和与纤维蛋白沉积相关的其他病理情况中非常有用。
• 3-(Imidazolyl)-2-alkoxypropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030199522A1

  公开（公告）日：2003-10-23

  Compounds according to formula (I) wherein n is 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式（I）中的化合物，其中n为0-3，R1为可选择的取代C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2、R3、R4、R5、R6、R7、R8和R9分别独立选择自氢和可选择取代的C1-6烷基，或R5和R8为烷基链，是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理条件中具有用途。
• Novel chromogenic substances and use thereof for the determination of carboxypeptidase activities
  申请人：Quentin Gerard

  公开号：US20050107305A1

  公开（公告）日：2005-05-19

  The invention relates to chromogenic compounds and the use thereof for the determination of enzymes of the family of carboxypeptidases N and carboxypeptidases U. The above is more specifically a compound of formula (I) in which A=(1), (2), (3), (4) or (5). R1. R2=H. —CH 3 , —CH(CH 3 ) 2 , —OCH 3 , —Cl.—CF 3 ,—OCF 3 ,—SCH 3 , R 3 =an amino acid group which may be hydrolysed by a carboxypeptidase A and R 4 =a basic amino acid group.

  该发明涉及变色化合物及其用于测定羧肽酶N和羧肽酶U家族酶的用途。具体而言，上述是一种具有化学式(I)的化合物，其中A=(1)、(2)、(3)、(4)或(5)。R1、R2=H、—CH3、—CH(CH3)2、—OCH3、—Cl、—CF3、—OCF3、—SCH3，R3=可能被羧肽酶A水解的氨基酸基团，R4=一种碱性氨基酸基团。